References
- Brar JE, Nader ND. (2014). Immune minimization strategies in renal transplantation. Immunol Invest. 43, 807–18
- Ebrahimi A, Rahim F. (2014). Recent immunomodulatory strategies in transplantation. Immunol Invest. 43, 829–37
- Edozie FC, Nova-Lamperti EA, Estafania A, et al. (2014). Regulatory T-cell therapy in the induction of transplant tolerance: The issue of subpopulations. Transplantation, 98, 370–9
- Hu, K, Zhou H, Zheng G., et al. (2014). Imbalance of different types of CD4 + FoxP3+ T cells in renal transplant recipients. Immunol Invest. 43, 838–50
- Inoue H, Nagata N, Kurokawa H, Yamanaka S. (2014). iPS cells: a game changer for future medicine. Embo J, 33, 409–17
- Kumar V, Kumar A. (2014). Immunological aspects of corneal transplantation. Immunol Invest. 43, 888–901
- Laftavi MR, Sharma R, Feng L, et al. (2014). Induction therapy in renal transplant recipients: A review. Immunol Invest. 43, 790–806
- Maguire O, Tario Jr JD, Shanahan TC, et al. (2014). Flow cytometry and solid organ transplantation: a perfect match. Immunol Invest. 43, 756–74
- Manjili MH, Toor AA. (2014). Etiology of GVHD: alloreactivity or impaired cellular adaptation? Immunol Invest. 43, 851–7
- Mosaad YM. (2014). Immunology of hematopoietic stem cell transplant. Immunogical Investigations. 43, 858–87
- Pankewycz O, Soliman K, Laftavi MR. (2014). The increasing clincal importance of alloantibodies in kidney transplantation. Immunol Invest. 43, 775–89
- Rey D, Vargas-Alarcon G, Areces C, et al. (2014). Mixtec mexican amerindians: An HLA alleles study for america peopling, pharmacogenomics and transplantation. Immunol Invest. 43, 738–55
- Soliman K, Mogadam E, Laftavi M, et al. (2014). Long-term outcomes following sirolimus conversion after renal transplantation. Immunol Invest. 43, 819–28